Telisotuzumab vedotin is a Monoclonal Antibody Conjugated owned by AbbVie, and is involved in 7 clinical trials, of which 2 were completed, and 5 are ongoing.

Telisotuzumab vedotin (ABBV-399, ABT-399) exhibits therapeutic intervention by targeting and binding to hepatocyte growth factor receptor expressed on tumor cell surface and inhibiting c-Met signaling pathway, thereby showing the cytotoxic effect, which leads to prevention of growth and proliferation of cancer cells.

The revenue for Telisotuzumab vedotin is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Telisotuzumab vedotin NPV Report.

Telisotuzumab vedotin is originated and owned by AbbVie.

Telisotuzumab vedotin Overview

Telisotuzumab vedotin (ABBV-399, ABT-399) is under development for the treatment of advanced solid tumors like advanced/metastatic non-squamous non-small cell lung cancer, squamous cell lung cancer and non-small cell lung cancer. The drug candidate administered is through intravenous infusion. It is an antibody-drug conjugate (ADC). It targets the c-MET(hepatocyte growth factor receptor ).

AbbVie Overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$56,197 million for the fiscal year ended December 2021 (FY2021), an increase of 22.7% over FY2020. In FY2021, the company’s operating margin was 31.9%, compared to an operating margin of 24.8% in FY2020. In FY2021, the company recorded a net margin of 20.5%, compared to a net margin of 10.1% in FY2020. The company reported revenues of US$14,812 million for the third quarter ended September 2022, an increase of 1.6% over the previous quarter.

Quick View – Telisotuzumab vedotin

Report Segments
  • Innovator
Drug Name
  • Telisotuzumab vedotin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.